Dipyaman Ganguly

  • user
  • User logout

Other links:

Other links:

Man with glasses and a beard, wearing a black jacket and white shirt, standing outdoors.

Dipyaman Ganguly

Head of the Department, Biology, Professor of Biology, Ashoka University

Ph.D. University of Texas
dipyaman.ganguly@ashoka.edu.in

Professor Dipyaman Ganguly is a physician-scientist working on human immunology, currently a Professor in the Department of Biology at Ashoka University. He did his MBBS from Medical College, Kolkata, India, a PhD in Biotechnology from Indian Institute of Chemical Biology, Kolkata, India and another PhD in Immunology from UT MD Anderson Cancer Center, Houston, USA. After his postdoctoral research in Columbia University, New York City, USA, Prof. Ganguly came back to India in 2013, to start his independent laboratory in CSIR-Indian Institute of Chemical Biology, Kolkata, where he continued his research till 2024.

The major research interests in Prof. Ganguly’s laboratory are in immunobiology of plasmacytoid dendritic cells in health and in the clinical contexts of autoreactive inflammation, as well as exploring the role of mechanical cues in human immune cellular functions. In addition, his laboratory has been closely engaged in several clinical trial efforts to map clinically relevant heterogeneity of immune response in the population through multi-omics immunophenotyping.

Prof. Ganguly is a recipient of NASI-Scopus Young Scientist Award (2017), Swarnajayanti Fellowship from Dept. of Science and Technology (2017), CDRI Award from CSIR-Central Drug Research Institute, India (2018), National Bioscience Award from Dept. of Biotechnology (2018), Merck Young Scientist Award (2019) and Shanti Swarup Bhatnagar Prize in Medical Sciences from Council of Scientific and Industrial Research, India (2022). He is an elected Fellow of Indian Academy of Sciences, National Academy of Medical Sciences, India, and Royal Society of Biology, UK.

Area of research: Dendritic cell biology and autoreactive inflammation

  • Bandopadhyay P, .. Ganguly D*. Cutting Edge: ATP13A2 is an endo-lysosomal regulator of TLR9/7 activation in human plasmacytoid dendritic cells. Journal of Immunology, 2024 Jul 15;213(2):109-114.
  • Ghosh AR#, Bandopadhyay P#, .. Ganguly D*. Mitochondrial sourcing of interferogenic ligands and an autoantigen in human obesity-associated metaflammation. Obesity. 2023 Jul 26.
  • Ganguly D*. Multi-omics studies in interpreting the evolving standard model for immune functions (Review). Briefings in Functional Genomics, 2023. Mar 10:elad003.
  • Liu B, .. Ganguly D, Zhao J, Yang CY*. The RNase MCPIP3 promotes skin inflammation by orchestrating myeloid cytokine response. Nature Communications, 2021 Jul 2;12(1):4105.
  • Raychaudhuri D, .. Ganguly D*. Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells. Frontiers in Immunology. 2019 Aug 7;10:1878. doi: 10.3389/fimmu.2019.01878.
  • Rahaman O, .. Ganguly D*. Cutting Edge: Dysregulated endocannabinoid-rheostat for plasmacytoid dendritic cell activation in a systemic lupus endophenotype. Journal of Immunology, 2019 Mar 15;202(6):1674-1679.
  • Ganguly D*. Do type I interferons link systemic autoimmunities and metabolic syndrome in a pathogenetic continuum? (Review) Trends in Immunology, 2018 Jan;39(1):28-43.
  • Nargis T, .. Ganguly D*, Chakrabarti P*. KLK5 induces shedding of DPP4 from circulatory Th17 cells in Type 2 Diabetes. Molecular Metabolism, 2017 Nov;6(11):1529-1539.
  • Ghosh AR, .. Ganguly D*. Adipose Recruitment and Activation of Plasmacytoid Dendritic Cells Fuel Metaflammation. Diabetes. 2016 Aug 25. 65 (11): 3440-3452.
  • Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, .. Gilliet M*. TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nature Immunology. 2015 Sep;16(9):970-9.
  • Sisirak V#, Ganguly D#, .., Reizis B (#equal contribution). Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. Journal of Experimental Medicine. 2014. Sep 22;211(10):1969-76.
  • Ganguly D, Haak S, Sisirak V, Reizis B*. Role of dendritic cells in autoimmunity (Review). Nature Reviews Immunology. 2013 Aug;13(8):566-77.
  • Di Domizio J, .. Cao W*. Nucleic acid-containing amyloid fibrils potently induce type I interferon and stimulate systemic autoimmunity. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14550-5.
  • Lande R, Ganguly D, .., Gilliet M*. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Science Translational Medicine. 2011 Mar 9;3(73):73ra19. doi: 10.1126/scitranslmed.3001180.
  • Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. Journal of Experimental Medicine. 2009 Aug 31;206(9):1983-94. doi: 10.1084/jem.20090480.

 

Area of research: Role of mechanical cues in immune cells:

  • Liu CSC*, Biswas P, Ganguly D*. Measuring Piezo1 and actin polarity in chemokine-stimulated Jurkat cells during live-cell imaging. BioProtocol, 2024 Oct 5;14(19):e5079.
  • Goon S#, Liu CSC#, .. Ganguly D*, Talukdar A*. Exploring the structural attributes of Yoda1 for the development of new-generation Piezo1 agonist Yaddle1 as vaccine adjuvant targeting optimal T-cell activation. Journal of Medicinal Chemistry, 2024 May 23;67(10):8225-8246.
  • Liu CSC, .. Ganguly D*. Piezo1 mechanosensing regulates integrin-dependent chemotactic migration in human T cell. eLife, 2024 Feb 23;12:RP91903.
  • Liu CSC, Ganguly D*. Mechanical Cues for T Cell Activation: Role of Piezo1 Mechanosensors (Review). Critical Reviews in Immunology 2019. Epub. DOI: 10.1615/CritRevImmunol.2019029595
  • Liu CSC, .. Ganguly D*. Cutting Edge: Piezo1 mechanosensors optimize human T cell activation. Journal of Immunology, 2018 Feb 15;200(4):1255-1260.

Area of research: Therapeutic targeting of plasmacytoid dendritic cells and type I IFNs
(Collaboration with Dr. Arindam Talukdar, CSIR-IICB, India)

  • Das N#, Bandopadhyay P#, Roy S#, .. Ganguly D*, Talukdar A*. Development, Optimization and In-vivo Validation of New Imidazopyridine Chemotype as Dual TLR7/TLR9 Antagonists Through Activity Directed Sequential Incorporation of Relevant Structural Sub-units. Journal of Medicinal Chemistry. 2022 Sep 8;65(17):11607-11632.
  • Kundu B#, Raychaudhuri D#, Mukherjee A#, Sinha BP#, .. Ganguly D*, Talukdar A*. Systematic Optimization of Potent and Orally Bioavailable Purine-Scaffold Dual Inhibitor for Toll-Like Receptors 7 and 9. Journal of Medicinal Chemistry. 2021. Jul 8;64(13):9279-9301.
  • Talukdar A*, Ganguly D, Roy S, Das N, Sarkar D. Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors (Review). Journal of Medicinal Chemistry. 2021 Jun 24;64(12):8010-8041.
  • Mukherjee A#, Raychaudhuri D#, Sinha BP#, .. Ganguly D*, Talukdar A*. A chemical switch for transforming a purine agonist for toll-like receptor 7 to a clinically relevant antagonist. Journal of Medicinal Chemistry. 2020 May 14;63(9):4776-4789.
  • Paul B#, Rahaman O#, .. Ganguly D*, Talukdar A*. Activity-guided development of potent and selective toll-like receptor 9 antagonists. European Journal of Medicinal Chemistry. 2018 Nov 5;159:187-205.
  • Roy S, .. Ganguly D*, Talukdar A*. Design and development of benzoxazole derivatives with toll-like receptor 9 antagonism. European Journal of Medicinal Chemistry. 2017 Jul 7;134:334-347. doi: 10.1016/j.ejmech.2017.03.086.

 

Area of research: Response to pandemic – COVID-19 immunopathology and clinical trial

  • Mehta P, .. Ganguly D, Pandey R*. Suppressed transcript diversity and immune response in COVID-19 ICU patients: a longitudinal study. Life Science Alliance. 2023 Nov 2;7(1):e202302305.
  • Sinha BP, .. Pandey R*, Basu K*, Ganguly D*. Deficient phagocytosis in circulating monocytes from patients with COVID-19-associated mucormycosis. mBio, 2023 Jun 27;14(3):e0059023. doi: 10.1128/mbio.00590-23.
  • D’Rozario R, .. Ganguly D*. Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. Viruses. 2023 Feb 16;15(2):549.
  • Raychaudhuri D, .. Ganguly D*. Clinical trial sub-group analyses to investigate clinical and immunological outcomes of convalescent plasma therapy in severe COVID-19. Mayo Clinic Proceedings: Innovation, Quality & Outcome. 2022 Dec;6(6):511-524.
  • Ray Y*, .. Ganguly D*. A Phase 2 Single Center Open Label Randomised Control Trial for Convalescent Plasma Therapy in Patients with Severe COVID-19. Nature Communications, 2022, 13(1):383.
  • Park H, Tarpey T, Liu M, Goldfeld K, Wu Y, Wu D, Li Y, Zhang J, Ganguly D, .. Petkova E*. Development and Validation of a Treatment Benefit Index to Identify Who May Benefit from Convalescent Plasma among Patients Hospitalized With COVID-19. JAMA Network Open. 2022, in press.
  • Sarif J#, Raychaudhuri D#, D’Rozario R#, Bandopadhyay P#, Singh P#, Mehta P#, .. Sengupta S*, Ganguly D*. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19. Frontiers in Immunology. 2021 Oct 28;12:738093.
  • Bandopadhyay P#, Rozario R#, Lahiri A#, Sarif J#, Ray Y#, Paul SR#, .. Ganguly D*. Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19. Journal of Infectious Diseases. 2021. Aug 16;224(4):565-574.

 

Patents:

1. Inhibitors of phosphatidylinositol-3-kinase and nitric oxide. US Patent: US-20120190738-A1, granted in 2016.
2. Blocking toll-like receptor 9 signalling using small molecule antagonists. US Patent: US-10662177-B2, granted in 2020.
3. Purine based compounds as toll-like receptor 9 antagonists. US Patent: US-11168084-B2, granted in 2021.

 

Monographs:

Ganguly D. Plasmacytoid Dendritic Cells. Springer-Verlag. ISBN-13: 9789811955945.

 

Book chapters:

  • Bandopadhyay P, Ganguly D. Host immune responses in COVID-19: Implication for Pre-existing Chronic Systemic Inflammation. Book chapter in ‘Genomic Surveillance and Pandemic Preparedness’ 1st Edition 2023, Elsevier.
  • Mukhopadhyay S, Dutta D, Ganguly D. Psoriasis and Diabetes: An association likely missed. Book chapter in ‘Psoriasis and Psoriatic Arthritis: Pathophysiology and Therapeutic Interventions’ 1st edition 2018, Taylor & Francis.
  • Mukhopadhyay S, Dutta D, Ganguly D. Lipid induced insulin resistance: Molecular Mechanisms and Clinical Implications. Book chapter in ‘Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome’ 2nd edition 2018, Elsevier.
  • Talukdar A, Ganguly D. Small Molecule Inhibitors of Toll-like Receptors. Book chapter in ‘Protein–Protein and Protein–Nucleic Acid Interaction Regulators; Drug Discovery Series’ 1st edition 2020, Royal Society of Chemistry.
  • Ghosh AR, Bandopadhyay P, Ganguly D. Type I Interferons in Metabolic Syndrome. Book chapter in ‘Metabolic Syndrome: From mechanisms to interventions’ 1st edition in press, Elsevier.
  • Bandopadhyay P, Ganguly D. Dysbiosis of Human Microbiome and Metabolic Diseases. Book Chapter in ‘Human Microbiome in Health and Diseases, Volume A’ 1st edition, Elsevier.
  • Ganguly D. The endocannabinoid system in the immunobiology of dendritic cells. Book Chapter in ‘Cannabis, Cannabinoids and endocannabinoids’ 1st edition in press, Elsevier.

2024- Elected Fellow of National Academy of Medical Sciences (FAMS), India.
2024- Elected Fellow of Royal Society of Biology (FRSB), UK.
2024- Elected Fellow of Indian Academy of Sciences (FASc), Bangalore, India. (https://www.ias.ac.in/; https://fellows.ias.ac.in/profile/v/FL2024013)
2022- Shanti Swarup Bhatnagar Prize in Medical Sciences, from Council of Scientific and Industrial Research, India. (https://ssbprize.gov.in/Content/NewsandPublish.aspx?m_id=1&ID=68 )
2019- Merck Young Scientist Award in Life Sciences, from Merck, India (https://mpoweringlifescience.com/mysa/)
2019- CDRI Award for Excellence in Drug Research Life Sciences, from Central Drug Research Institute, India (https://indiabioscience.org/grants/cdri-awards-2022-for-excellence-in-drug-research)
2017- National Bioscience Award for Career Development, from Dept. Of Biotechnology, Govt. of India (https://en.wikipedia.org/wiki/National_Bioscience_Award_for_Career_Development)
2017- Swarnajayanti Fellowship in Life Sciences, from Dept. of Science & Technology, Govt. of India (https://en.wikipedia.org/wiki/Swarnajayanti_Fellowship)
2017- NASI Scopus Young Scientist Award in Medicine, from National Academy of Science India and Elsevier (https://www.elsevier.com/en-in/solutions/scopus/scopus-awards-2022)
2016- Invited to deliver Plenary lecture in the 14th International Symposium on Dendritic cells, Shanghai, China.
2015- Invited to Overseas Outstanding Young Scholars Forum, Sun Yat-sen University & Zhongshan Medical School, Guangzhou, China.
2011- Ramanujan Fellowship, Dept. of Science & Technology, Govt. of India.
2011- Lupus Foundation Postdoctoral Fellowship from the S.L.E. Foundation, New York.
2009- Keystone Symposium Travel Scholarship.
2007- Vivian L. Smith Outstanding Young Immunologist Award from the Center for Cancer Immunology Research, UT MD Anderson Cancer Center, Houston, Texas, USA.

Study at Ashoka

Study at Ashoka

    Sticky Button